A few days ago, a number of technological innovation projects covering major industries of the national economy supported by the Ministry of Science and Technology have been “unveiled” one after another. The Guangdong Provincial Department of Science and Technology officially released the “Guangdong Provincial Department of Science and Technology on the 2020 “Technology Assists the Economy 2020″ Key Special Projects” “Notice of Project Plan”, among which the “Drug Research and Development of Mesenchymal Stem Cells for the Treatment of New Coronavirus Pneumonia” led by Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as “Beike Biotechnology”) was successfully selected and won the key special recommendation project of “Guangdong Province Science and Technology Assists the Economy 2020”.
The “Science and Technology Powers the Economy 2020” key project is a national key R&D plan implemented by the Ministry of Science and Technology to implement the decisions and arrangements of the Party Central Committee and the State Council on coordinating the key tasks of epidemic prevention and control and economic and social development, and to actively and orderly promote the resumption of work and production of enterprises. It aims to support a number of technological innovation projects covering major industries of the national economy, especially the transformation and implementation projects of technological achievements that can see practical results in the short term and directly promote the resumption of work and production.
Beike Biotech was founded in 2005. It is one of the earliest national high-tech enterprises in my country specializing in the clinical transformation and technical services of biotherapeutic technologies in strategic emerging industries. Having been deeply involved in the cell industry for 15 years, Beike Biotech hasHas a top-notch mature stem cell research team and cutting-edge cell storage and preparation technology, innovative and pioneeringThe industrial development model of “comprehensive cell bank + regional cell intelligent manufacturing center + cell quality testing platform” is Clinical transformation of cell therapy technology provides a complete technical platform and infrastructure.
During the epidemic, Beike Biotech has always been working on the front line of anti-epidemic work, responding to the country’s call in the shortest time and fastest by investing its scientific research resources in the treatment of severely ill patients infected with 2019-nCoV. Applied for cooperation with Shenzhen Third People’s Hospital“Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe Pneumonia Caused by Coronavirus”The project was awardedGuangdong Provincial Department of Science and Technology’s 2020 Guangdong Provincial New Coronavirus Prevention and Control Emergency Emergency Project. At the same time, the clinical research on mesenchymal stem cells for the treatment of critically ill patients with COVID-19, jointly conducted by Beike Biotech and several medical institutions in Yunnan, has achieved preliminary results and has been published. font-family: inherit; vertical-align: baseline;”>The article “Human umbilical cord mesenchymal stem cells combined with antiviral and other methods to treat novel coronavirus pneumonia” contributes to the fight against the epidemic.
In addition, Beike Biotech has also been insisting on R&D innovation in the field of cells, actively participating in clinical research of mesenchymal stem cells in refractory diseases, and has collaborated with clinical institutions to publish more than 100 domestic and foreign papers. Beike Biological Research Results“Key technological innovation and clinical application of allogeneic mesenchymal stem cells in the treatment of refractory lupus erythematosus”Received2019 National Technology Invention Award!
It is reported that Guangdong Province has received a total of 29.5 million special project funds this time to help a total of 49 companies involving biomedicine and life and health, artificial intelligence, energy materials and other fields.